• Trump ordered 100% tariffs on certain patented drugs unless companies negotiate pricing deals.
• Pharmaceutical firms have a limited time to comply, with larger companies given 120 days.
• The tariff aims to enhance U.S. production and decrease reliance on imports.
• Critics warn that tariffs could increase drug prices and impact investment in the sector.
• Trade agreements with the EU, Japan, South Korea, and Switzerland will cap tariffs at 15%.

U.S. President Donald Trump has enacted significant tariffs of up to 100% on certain patented pharmaceuticals that do not reach agreements with the government. This decision reflects his administration's goal to bolster domestic manufacturing and reduce the national security risks associated with pharmaceutical imports, according to BBC, Reuters, and Al Jazeera.

Companies that are willing to enter a "most favoured nation" pricing deal and construct facilities in the U.S. could benefit from a zero-percent tariff. For those merely shifting some manufacturing to the U.S., a 20% tariff will apply, escalating to 100% within four years if no deal is struck, as outlined in Trump's executive order. The U.S. will allow 120 days for larger firms and 180 days for smaller ones to finalize agreements before the elevated tariffs are enforced, according to Reuters and Al Jazeera.

While the administration has reported securing 17 pricing deals with major drug manufacturers—13 of which have been confirmed—critics are raising alarms about the potential for increased healthcare costs. The U.S. Chamber of Commerce has warned that these new tariffs may further burden consumers, suggesting healthcare costs will rise as a direct consequence of the tariffs imposed on pharmaceuticals, as noted by BBC and Reuters.

Additionally, certain international agreements are also in play, capping tariffs at 15% for pharmaceutical imports from the European Union, Japan, South Korea, and Switzerland. The UK has achieved a notably favorable arrangement allowing for a zero-percent tariff on exports to the U.S. for at least three years. As several major countries have begun negotiating similar deals, concerns linger regarding the balance of supporting U.S. manufacturing while managing the implications for domestic healthcare costs, according to Reuters and Al Jazeera.